<DOC>
	<DOCNO>NCT02182765</DOCNO>
	<brief_summary>Study determine effect 28 day nevirapine treatment steady-state pharmacokinetics amprenavir abacavir evaluate pharmacokinetics nevirapine combination amprenavir abacavir compare historical control treat nevirapine without amprenavir abacavir . In addition safety/tolerance nevirapine , amprenavir abacavir assess base adverse event clinical laboratory data .</brief_summary>
	<brief_title>Investigation Potential Pharmacokinetic Interaction Between Nevirapine , Abacavir Amprenavir HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor ( NNRTI ) Naive Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<criteria>Male female patient age 18 65 year , inclusive ; Plasma HIV1 RNA &gt; = 5000 copies/mL , document HIV1 infection CD4+ cell count &gt; = 100 cells/mm³ Patients meet follow laboratory parameter : Lymphocyte count &gt; = 1000 cells/mm³ Hemoglobin &gt; = 9.0 g/dl ( men woman ) Platelet count &gt; = 75000 cells/mm3 Alkaline Phosphatase &lt; = 3.0 time upper limit normal Serum GlutamicOxaloacetic Transaminase ( SGOT ) Serum GlutamicPyruvic Transaminase ( SGPT ) &lt; = 3.0 time upper limit normal Total bilirubin &lt; = 1.5 time upper limit normal Creatinine &lt; = 2mg/dL Female patient reproductive potential willing use reliable method doublebarrier contraception ( diaphragm spermicidal cream jelly , condom spermicidal foam ) Patients inform willing able comply investigational nature study sign write consent accordance institutional federal guideline Female patient pregnant breastfeed Female patient intend change doublebarrier contraception method within 28 day prior Study Day 0 throughout trial Patients opinion investigator require treatment prohibit medication study include potentially toxic substrate terfenadine , bepridil , astemizole , cisapride , triazolam , midazolam ergotamine/dihydroergotamine contain regime Patients take know inhibitor inducer Cytochrome P450 metabolic enzyme include macrolide antibiotic ( erythromycin , clarithromycin , azithromycin ) azole antifungal ( fluconazole , itraconazole ) phenytoin within 28 day prior Study day 0 throughout trial Patients receive immunomodulatory agent Ketoconazole , rifabutin rifampin exclude screen throughout trial Patients previous exposure antiretroviral , delavirdine , loviride , efavirenz , nevirapine , abacavir , saquinavir , ritonavir , indinavir , nelfinavir , amprenavir , zidovudine , Lamivudine ( 3TC ) , Stavudine ( d4T ) , Didanosine ( ddI ) Zalcitabine ( ddC ) Patients receive investigational drug systemic corticosteroid within 30 day first dose study medication system corticosteroid initially well throughout study antineoplastic agent radiotherapy local skin radiotherapy treatment within 12 week start study medication Patients malabsorption , severe chronic diarrhea patient unable maintain adequate oral intake Patients currently abuse alcohol substance abusing ; patient methadone substitution program might consider inclusion trial Patients undergoing treatment active infection Patients hepatic insufficiency due cirrhosis Patients renal insufficiency Patients heavy smoker ( e.g . &gt; 20 cigarette per day ) Patients whose reliability deem put risk noncompliance study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>